What Does the Market Think About Penumbra? - Penumbra ( NYSE:PEN )
Penumbra's PEN short percent of float has fallen 17.98% since its last report. The company recently reported that it has 1.52 million shares sold short, which is 5.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.55 days to cover their ...
Penumbra PEN Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Tuesday, July 29, 2025 at 8:30 p.m. ETChairman and Chief Executive Officer - Adam ElsesserContinue reading ...
Penumbra ( PEN ) Q2 Revenue Jumps 13%
Penumbra ( NYSE:PEN ) , a medical device innovator focused on clot removal and vascular care, reported its second quarter 2025 results on July 29, 2025. The company delivered $339.5 million in GAAP revenue and $0.86 in non-GAAP earnings per share, Revenue exceeded analyst expectations.
Teradyne, Littelfuse, Marvell Technology, Cheesecake Factory And Other Big Stocks Moving Higher On Wednesday - Biohaven ( NYSE:BHVN ) , Ashland ( NYSE:ASH )
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Teradyne Inc TER rose sharply during Wednesday's session following better-than-expected Q2 EPS and sales. Teradyne reported quarterly earnings of 57 cents per share which beat the analyst consensus ...
Penumbra ( PEN ) Surpasses Q2 Earnings and Revenue Estimates
Penumbra (PEN) delivered earnings and revenue surprises of +6.17% and +3.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ITGR vs. PEN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer ( ITGR Quick QuoteITGR - ) or Penumbra ( PEN Quick QuotePEN - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Will Penumbra ( PEN ) Beat Estimates Again in Its Next Earnings Report?
Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Mettler-Toledo ( MTD ) Expected to Beat Earnings Estimates: Should You Buy?
Mettler-Toledo (MTD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra ( PEN ) Reports Next Week: Wall Street Expects Earnings Growth
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ITGR or PEN: Which Is the Better Value Stock Right Now?
ITGR vs. PEN: Which Stock Is the Better Value Option?
ITGR vs. PEN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Instruments stocks have likely encountered both Integer ( ITGR Quick QuoteITGR - ) and Penumbra ( PEN Quick QuotePEN - ) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Peering Into Penumbra's Recent Short Interest - Penumbra ( NYSE:PEN )
Penumbra's PEN short percent of float has fallen 14.44% since its last report. The company recently reported that it has 1.29 million shares sold short, which is 4.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.89 days to cover their ...
Is First Trust Health Care AlphaDEX ETF ( FXH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
ITGR or PEN: Which Is the Better Value Stock Right Now?
ITGR vs. PEN: Which Stock Is the Better Value Option?
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.
PEN Stock Rises Following the Launch of Ruby XL System
Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.
Should You Invest in the First Trust Health Care AlphaDEX ETF ( FXH ) ?
Sector ETF report for ...
Why Is Penumbra ( PEN ) Down 10.6% Since Last Earnings Report?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Penumbra Rallies 35.9% in a Year: What's Driving the Stock?
PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.
What's Driving the Market Sentiment Around Penumbra? - Penumbra ( NYSE:PEN )
Penumbra's PEN short percent of float has risen 4.22% since its last report. The company recently reported that it has 1.57 million shares sold short, which is 5.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.35 days to cover their ...
3 Reasons Growth Investors Will Love Penumbra ( PEN )
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst - Penumbra ( NYSE:PEN )
Q1 sales rose 16.3% to $324.1 million, topping the $315.66 million estimate. U.S. thrombectomy revenue jumped 25% to $187.9 million in Q1 2025. Today's manic market swings are creating the perfect setup for Matt's next volatility trade. Get his next trade alert for free, right here.
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
Penumbra ( PEN ) Q1 Earnings and Revenues Top Estimates
Penumbra (PEN) delivered earnings and revenue surprises of 25.76% and 2.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Penumbra, Inc. ( NYSE: PEN ) and Encourages Current Penumbra Shareholders to Contact the Firm - Penumbra ( NYSE:PEN )
PHILADELPHIA, April 21, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Kaskela Law LLC is investigating Penumbra, Inc. PEN on behalf of the company's current shareholders.
Why Penumbra ( PEN ) is Poised to Beat Earnings Estimates Again
Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Integer ( ITGR ) Earnings Expected to Grow: Should You Buy?
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra ( PEN ) Earnings Expected to Grow: Should You Buy?
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Penumbra Gaining or Losing Market Support? - Penumbra ( NYSE:PEN )
Penumbra's PEN short percent of float has fallen 9.64% since its last report. The company recently reported that it has 1.22 million shares sold short, which is 4.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.96 days to cover their ...
Tandem Diabetes Care ( TNDM ) Moves 7.6% Higher: Will This Strength Last?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts.
Veracyte ( VCYT ) Up 0.7% Since Last Earnings Report: Can It Continue?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues
Penumbra expects to materially increase both revenues and profitability in the company's international business in the next few years.
Penumbra ( PEN ) Down 8% Since Last Earnings Report: Can It Rebound?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Peering Into Penumbra's Recent Short Interest - Penumbra ( NYSE:PEN )
Penumbra's PEN short percent of float has fallen 19.16% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 4.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.02 days to cover their ...
Neurology Devices Market is Expected to Reach USD 22,335.5 Million by 2035, Growing at 6.7% CAGR | Fact.MR Report
Rockville, MD, March 10, 2025 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global neurology devices market is estimated to reach a valuation of USD 11,678 million in 2025 and is expected to grow at a CAGR of 6.7% during the forecast ...
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail
Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.
BAX Stock Surges Following Q4 Earnings & Sales Beat, Margins Decline
Baxter reports better-than-expected fourth-quarter results. However, the company's gross and operating margins contract. Shares rise in pre-market.
Penumbra ( PEN ) Upgraded to Buy: Here's Why
Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook - Penumbra ( NYSE:PEN )
Penumbra reported Q4 sales of $315.52 million, up 10.8% Y/Y, beating estimates of $311.55 million. U.S. thrombectomy sales jumped 27.3%, driving global growth of 15.4%. Get access to your new suite of high-powered trading tools, including real-time stock ratings, insider trades, and government ...
Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday - Andersons ( NASDAQ:ANDE ) , Analog Devices ( NASDAQ:ADI )
U.S. stocks were lower, with the Dow Jones falling over 200 points on Wednesday. Shares of Garmin Ltd. GRMN rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results and FY25 outlook. It also recommended 20% dividend hike.
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises
Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.
Penumbra ( PEN ) Beats Q4 Earnings and Revenue Estimates
Penumbra (PEN) delivered earnings and revenue surprises of 6.59% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
HOLX's New Offerings Likely to Revive Stock Amid Macro Woes
Hologic's Surgical business has been recording strong broad-based performance by expanding access to technologies into new global markets.
TMO Stock Set to Gain From The Launch of New Spatial Imaging System
Thermo Fisher's Invitrogen EVOS S1000 Spatial Imaging System addresses the limitations of current fluorescent microscopy technologies.
ALGN Stock Gains on the Launch of Invisalign Palatal Expander in Turkey
Align Technology commercially launches its Invisalign Palatal Expander System in Turkey after approval from TMMDA.
Should You Add Penumbra Stock to Your Portfolio Right Now?
PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.
